Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells

BMC Cell Biology

Volumn 11, Issue , 2010, Pages

  Holzwarth, Christina ^a   Vaegler, Martin ^a   Gieseke, Friederike ^a   Pfister, Stefan M ^b   Handgretinger, Rupert ^a   Kerst, Gunter ^a   Müller, Ingo ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; OXYGEN RADICAL;

ADIPOGENESIS; ADOLESCENT; ADULT; ARTICLE; BONE DEVELOPMENT; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL HYPOXIA; CELL LYSATE; CELL PROLIFERATION; CELL STRESS; CELL STRUCTURE; CHILD; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; OXYGEN TENSION; PHENOTYPIC PLASTICITY; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; STROMA CELL; THROMBOCYTE; BONE MARROW CELL; CYTOLOGY; INFANT; METABOLISM;

ADOLESCENT; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CHROMOSOMAL INSTABILITY; FEMALE; G1 PHASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOPHENOTYPING; INFANT; MALE; MESENCHYMAL STEM CELLS; MULTIPOTENT STEM CELLS; STROMAL CELLS;

EID: 77349087595     PISSN: None     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-11-11     Document Type: Article

References (43)

1. Abdallah BM, Kassem M. The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. J Cell Physiol 2009, 218:9-12. 10.1002/jcp.21572, 18726996.
2. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
3. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002, 99:8932-8937. 10.1073/pnas.132252399, 124401, 12084934.
4. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441. 10.1016/S0140-6736(04)16104-7, 15121408.
5. Müller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, Dominici M, Greil J, Handgretinger R. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008, 40:25-32. 10.1016/j.bcmd.2007.06.021, 17869550.
6. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586. 10.1016/S0140-6736(08)60690-X, 18468541.
7. Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, Horwitz E, Anneren G, Axelsson O, Nunn J, Ewald U, Norden-Lindeberg S, Jansson M, Dalton A, Astrom E, Westgren M. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005, 79:1607-1614. 10.1097/01.TP.0000159029.48678.93, 15940052.
8. Müller I, Vaegler M, Holzwarth C, Tzaribatchev N, Pfister SM, Schutt B, Reize P, Greil J, Handgretinger R, Rudert M. Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia 2008, 22:2054-2061. 10.1038/leu.2008.217, 18719618.
9. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007, 211:27-35. 10.1002/jcp.20959, 17226788.
10. Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, Kloss F, Gully C, Gassner R, Lepperdinger G. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell 2007, 6:745-757. 10.1111/j.1474-9726.2007.00336.x, 17925003.
11. Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 2001, 81:685-696. 10.1016/S0006-3495(01)75733-5, 1301545, 11463617.
12. D'Ippolito G, Diabira S, Howard GA, Roos BA, Schiller PC. Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells. Bone 2006, 39:513-522. 10.1016/j.bone.2006.02.061, 16616713.
13. Rochefort GY, Delorme B, Lopez A, Herault O, Bonnet P, Charbord P, Eder V, Domenech J. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006, 24:2202-2208. 10.1634/stemcells.2006-0164, 16778152.
14. Dominici M, Le Blanc K, Müller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317. 10.1080/14653240600855905, 16923606.
15. Fink T, Abildtrup L, Fogd K, Abdallah BM, Kassem M, Ebbesen P, Zachar V. Induction of adipocyte-like phenotype in human mesenchymal stem cells by hypoxia. Stem Cells 2004, 22:1346-1355. 10.1634/stemcells.2004-0038, 15579652.
16. Lennon DP, Edmison JM, Caplan AI. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J Cell Physiol 2001, 187:345-355. 10.1002/jcp.1081, 11319758.
17. Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, Jia M, Zhao Q, Cai H, Han ZC, Yang R, Chen G, Zhao RC. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun 2006, 347:12-21. 10.1016/j.bbrc.2006.05.169, 16814746.
18. Potier E, Ferreira E, Andriamanalijaona R, Pujol JP, Oudina K, Logeart-Avramoglou D, Petite H. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007, 40:1078-1087. 10.1016/j.bone.2006.11.024, 17276151.
19. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007, 358:948-953. 10.1016/j.bbrc.2007.05.054, 17521616.
20. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006, 20:161-171. 10.1016/j.blre.2005.11.002, 16364518.
21. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472. 10.1016/j.cell.2007.04.019, 17482542.
22. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007, 104:5431-5436. 10.1073/pnas.0701152104, 1838452, 17374716.
23. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 2008, 9:285-296. 10.1038/nrm2354, 18285802.
24. Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol 2007, 213:18-26. 10.1002/jcp.21081, 17458897.
25. Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz MP, Horwitz EM, Conte P, Handgretinger R, Dominici M. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006, 8:437-444. 10.1080/14653240600920782, 17050248.
26. Schallmoser K, Rohde E, Reinisch A, Bartmann C, Thaler D, Drexler C, Obenauf AC, Lanzer G, Linkesch W, Strunk D. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 2008, 14:185-196. 10.1089/ten.tec.2008.0060, 18620484.
27. Horn P, Bork S, Diehlmann A, Walenda T, Eckstein V, Ho AD, Wagner W. Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis. Cytotherapy 2008, 10:676-685. 10.1080/14653240802398845, 18985474.
28. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005, 205:228-236. 10.1002/jcp.20391, 15887229.
29. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251. 10.1038/bmt.2008.316, 18820709.
30. Egger M, Schgoer W, Beer AG, Jeschke J, Leierer J, Theurl M, Frauscher S, Tepper OM, Niederwanger A, Ritsch A, Kearney M, Wanschitz J, Gurtner GC, Fischer-Colbrie R, Weiss G, Piza-Katzer H, Losordo DW, Patsch JR, Schratzberger P, Kirchmair R. Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1alpha- and basic FGF-dependent pathway in muscle cells. FASEB J 2007, 21:2906-2917. 10.1096/fj.06-7440com, 17504977.
31. Li J, Shworak NW, Simons M. Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. J Cell Sci 2002, 115:1951-1959.
32. Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG. Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007, 39:396-400. 10.1080/00313020701444549, 17676480.
33. Tsai TT, Guttapalli A, Oguz E, Chen LH, Vaccaro AR, Albert TJ, Shapiro IM, Risbud MV. Fibroblast growth factor-2 maintains the differentiation potential of nucleus pulposus cells in vitro: implications for cell-based transplantation therapy. Spine (Phila Pa 1976) 2007, 32:495-502.
34. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006, 20:661-669. 10.1096/fj.05-5211com, 16581974.
35. Hung SC, Pochampally RR, Chen SC, Hsu SC, Prockop DJ. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25:2363-2370. 10.1634/stemcells.2006-0686, 17540857.
36. Shireman PK. The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 2007, 45(Suppl A):A48-A56. 10.1016/j.jvs.2007.02.030, 2680944, 17544024.
37. Gieseke F, Schutt B, Viebahn S, Koscielniak E, Friedrich W, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN{gamma}R1 signaling and IDO expression. Blood 2007, 110:2197-2200. 10.1182/blood-2007-04-083162, 17522338.
38. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621. 10.1182/blood-2003-11-3909, 15001472.
39. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997, 20:399-407. 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I, 9408757.
40. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, Korshunov A, Lichter P. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005, 23:8853-8862. 10.1200/JCO.2005.02.8589, 16314645.
41. Stange DE, Radlwimmer B, Schubert F, Traub F, Pich A, Toedt G, Mendrzyk F, Lehmann U, Eils R, Kreipe H, Lichter P. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res 2006, 12:345-352. 10.1158/1078-0432.CCR-05-1633, 16428471.
42. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE, Radlwimmer B, Lohmann DR, Lichter P. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 2005, 43:294-301. 10.1002/gcc.20186, 15834944.
43. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008, 118:1739-1749. 10.1172/JCI33656, 2289793, 18398503.